Global Custom Market Research Reports Provider Company

phone

Global Parkinson’s Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

  • Published Date: 06 Nov 2017
  • Number of Pages: 210
  • Category: Healthcare and Medical
  • Country: Global
Global Parkinsons Treatment Market:

Global parkinsons treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market forparkinsons treatment is projected to reach US$ XX Mn by 2023.

Parkinsons disease is the chronic, progressive neurodegenerative disorder that is characterized by rigidity, tremors, postural instability and bradykinesia (slowness of movement) and patients will also experience the significant non-motor symptoms like changes in the sleep disturbances, autonomic dysfunction and cognition and mood. The condition is caused due to the degeneration of the dopamine-producing cells of the substantia nigra. Parkinsons disease is non-fatal but it cannot be cured, that results in the poor quality of life and increases disability along with the disease progression. As per the World Health Organization, the total number of people with disability-adjusted life year because of Parkinsons disease was 1.7 Mn globally in 2015.

Recent advancements in the treatment of Parkinsons disease like the combination or multiple therapies in order to prolong the actions of the continuous stimulation of dopaminergic drugs, neurostimulation devices approvals, neuroprotective therapies which slows the prognosis of Parkinsons disease are anticipated to drive Parkinsons disease treatment market globally.Furthermore, increase in ageing of the population, a rise in the Parkinsonism prevalence around the globe, treatment affordability are the factors bolstering the demand for some of the Parkinsons disease treatment market. Factors such as loss of patent protection for some of the drugs, rise in competition from generic drugs of Parkinsonism, huge unmet needs in the market, delaying development and launch of new products in the market are the few restraints for the Parkinsons disease treatment market growth. High competition in the market from other improved Parkinsons disease management methods also hinders the growth of the Parkinsons Treatment Market.

The global Parkinsons Treatment Markethas been classified on the basis of treatment, end user, and geography.

Based on drug class, global Parkinsons Treatment Market is segmented into the following:

Monoamine Oxidase Inhibitors (MAO)
Dopamine Precursors
Catechol-o-methyltransferase Inhibitors (COMT)
Peripheral Decarboxylase Inhibitors
Others (Anticholinergics, Antihistaminics)

Based on distribution channel, global Parkinsons Treatment Market segmented as:

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Drug Stores

Parkinsons disease is predominantly treated by mature and long-standing therapies like dopamine agonists and levodopa, hence, generic medicines are dominating the market. Adipose-derived stem cell therapy, Repetitive transcranial magnetic stimulation device, and minimally invasive neurostimulation devices, among others, are the new advancements in the Parkinsons treatment. Healthcare professionals are adapting to the advancements in technologies that will offer better treatment quality when compared to conventional treatment and devices like stereotactic systems and ultrasonic aspirators. Drug manufacturers are introducing novel options for the treatment with the clear defined position in a market, specifically as the option in a reduction of motor fluctuations alongside levodopa therapy. Acquisitions, new product launches and Collaboration agreements are few strategies which were adopted by key players. For instance, in 2015 January, Neuropore Therapies Inc. entered into a commercialization agreement with UCB S.A, for commercialization of NPT200-11, a small molecule drug used to treat the Parkinsons disease.

Geographically, the global Parkinsons Treatment Market is segmented into five regions namely, Latin America, North America, Asia-Pacific, Europe, and the Middle East and Africa. North America dominates the global market for Parkinsons disease treatment owing to the good reimbursement policies and high prevalence of the disease. As per the Parkinsons disease Foundation, approximately every year 60,000 Americans were diagnosed with Parkinsons disease. Europe is anticipated to hold the 2nd highest market share in the global market due to the increase in R&D investments by major players, growing disability-adjusted life years is driving the growth of the European Parkinsons Treatment Market. As per the European Parkinsons Disease Association, the disease treatment cost in Europe was estimated at US$ 12.6 Mn in 2015 and is expected to double by 2030. Rising prevalence of the disease and increasing demand for new drug therapies are the key drivers of the market. About 6.3 million people suffer from Parkinsons disease according to the European Brain Council.

Some of the players in global Parkinsons Treatment Market include Salix Pharmaceuticals (U.S.), GlaxoSmithKline Plc. (U.K.), Wockhardt Limited (India), Impax Laboratories, Inc. (U.S), Novartis AG (Switzerland), Mylan N.V (U.S), Teva Pharmaceutical Industries Ltd.(Israel), Cipla Inc.(India), Par Pharmaceutical (U.S), and Apotex Inc (Canada)

In 2015, U.S.FDA approved RYTARY an extended-release oral capsule of carbidopa and levodopa belongs to the Impax Laboratories, Inc., to treat Parkinsons disease and its complications

In 2012, Neupro (Rotigotine Transdermal System) of UCB has received USFDA approval which is for the treatment of advanced stage of idiopathic Parkinsons disease

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitors overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startups details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Publisher Name : Precision Business Insights
1. Executive summary
2. Global Parkinsons Treatment Market Introduction
2.1. Global Parkinsons Treatment Market Taxonomy
2.2. Global Parkinsons Treatment MarketDefinitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. Global Parkinsons Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Parkinsons Treatment Market Dynamics Factors Impact Analysis
3.6. Global Parkinsons Treatment Market Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
4. Global Parkinsons Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 2023
4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Parkinsons Treatment Market, By Drug Class, 2012 - 2016 and Forecast, 2017 - 2023
5.1. Monoamine Oxidase Inhibitors (MAO)
5.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Dopamine Precursors
5.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Catechol-o-methyltransferase Inhibitors (COMT)
5.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Peripheral Decarboxylase Inhibitors
5.4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others (Anticholinergics, Antihistamines)
5.5.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. Global Parkinsons Treatment Market Forecast, By Distribution Channel, 2012 - 2016 and Forecast, 2017 - 2023
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
6.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Parkinsons Treatment Market Forecast, By Region, 2012 - 2016 and Forecast, 2017 - 2023
7.1. North America
7.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Parkinsons Treatment Market- Opportunity Analysis Index - By Drug Class, By Distribution Channel, and Region, 2017 2023
8. North America Parkinsons Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
8.1.1. Drug Class Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1.1. Monoamine Oxidase Inhibitors (MAO)
8.1.1.2. Dopamine Precursors
8.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
8.1.1.4. Peripheral Decarboxylase Inhibitors
8.1.1.5. Others (Anticholinergics, Antihistaminics)
8.1.2. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.1.2.1. Hospital Pharmacies
8.1.2.2. Retail Pharmacies
8.1.2.3. Online Pharmacies
8.1.3. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.1.3.1. U.S.
8.1.3.2. Canada
8.1.4. North America Parkinsons Treatment Market- Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 2023
8.1.5. North America Parkinsons Treatment Market Dynamics Trends
9. Europe Parkinsons Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.1.1. Drug Class Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Monoamine Oxidase Inhibitors (MAO)
9.1.1.2. Dopamine Precursors
9.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
9.1.1.4. Peripheral Decarboxylase Inhibitors
9.1.1.5. Others (Anticholinergics, Antihistaminics)
9.1.2. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Hospital Pharmacies
9.1.2.2. Retail Pharmacies
9.1.2.3. Online Pharmacies
9.1.3. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Germany
9.1.3.2. UK
9.1.3.3. France
9.1.3.4. Spain
9.1.3.5. Italy
9.1.3.6. Russia
9.1.3.7. Poland
9.1.3.8. Rest of Europe
9.1.4. Europe Parkinsons Treatment Market- Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 2023
9.1.5. Europe Parkinsons Treatment Market Dynamics Trends
10. Asia-Pacific Parkinsons Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.1.1. Drug Class Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Monoamine Oxidase Inhibitors (MAO)
10.1.1.2. Dopamine Precursors
10.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
10.1.1.4. Peripheral Decarboxylase Inhibitors
10.1.1.5. Others (Anticholinergics, Antihistaminics)
10.1.2. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Hospital Pharmacies
10.1.2.2. Retail Pharmacies
10.1.2.3. Online Pharmacies
10.1.3. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
10.1.3.1. Japan
10.1.3.2. China
10.1.3.3. India
10.1.3.4. ASEAN
10.1.3.5. Australia & New Zealand
10.1.3.6. Rest of Asia-Pacific
10.1.4. Asia-Pacific Parkinsons Treatment Market- Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 2023
10.1.5. Asia-Pacific Parkinsons Treatment Market Dynamics Trends
11. Latin America Parkinsons Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
11.1.1. Drug Class Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Monoamine Oxidase Inhibitors (MAO)
11.1.1.2. Dopamine Precursors
11.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
11.1.1.4. Peripheral Decarboxylase Inhibitors
11.1.1.5. Others (Anticholinergics, Antihistaminics)
11.1.2. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Hospital Pharmacies
11.1.2.2. Retail Pharmacies
11.1.2.3. Online Pharmacies
11.1.3. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Brazil
11.1.3.2. Mexico
11.1.3.3. Argentina
11.1.3.4. Venezuela
11.1.3.5. Rest of Latin America
11.1.4. Latin America Parkinsons Treatment Market- Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 2023
11.1.5. Latin America Parkinsons Treatment Market Dynamics Trends
12. Middle East & Africa Parkinsons Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
12.1.1. Drug Class Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Monoamine Oxidase Inhibitors (MAO)
12.1.1.2. Dopamine Precursors
12.1.1.3. Catechol-o-methyltransferase Inhibitors (COMT)
12.1.1.4. Peripheral Decarboxylase Inhibitors
12.1.1.5. Others (Anticholinergics, Antihistaminics)
12.1.2. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Hospital Pharmacies
12.1.2.2. Retail Pharmacies
12.1.2.3. Online Pharmacies
12.1.3. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.3.1. Gulf Cooperation Council (GCC) Countries
12.1.3.2. Israel
12.1.3.3. South Africa
12.1.3.4. Rest of MEA
12.1.4. MEA Parkinsons Treatment Market- Opportunity Analysis Index - By Drug Class, By Surgery, By Route of Administration, By Distribution Channel, and Country, 2017 2023
12.1.5. MEA Parkinsons Treatment Market Dynamics Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Salix Pharmaceuticals (U.S.)
13.2.2. GlaxoSmithKline Plc. (U.K.)
13.2.3. Wockhardt Limited (India)
13.2.4. Impax Laboratories, Inc. (U.S)
13.2.5. Novartis AG (Switzerland)
13.2.6. Mylan N.V (U.S)
13.2.7. Teva Pharmaceutical Industries Ltd.(Israel)
13.2.8. Cipla Inc.(India)
13.2.9. Par Pharmaceutical (U.S)
13.2.10. Apotex Inc (Canada)
14. Research Methodology
15. Key Assumptions and Acronyms


In this report, the global Zipper market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at

View Report

In this report, the global Work Apparel market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing

View Report

In this report, the global Womens Handbags market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports